NCT Number: NCT06437574
Phase: PHASE2
Trial Summary: To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Cedars-Sinai Medical Center
Acronym:
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives